Evidence map›Paper›PMID 41158712›Full record

ArticleMaterials today. Bio2025

Carrier-free procyanidin-ferric nanonetworks loading gefitinib to inhibit TMEM16A-EGFR mutual activation loop for photothermally enhanced breast cancer targeted therapy.

Gen Li, Chunxiu Cai, Ning Zhang, Zijia Wang, Mingzhe Zhang, Quan Liu, Siyu Chen, Yanfei Shang, Chengqing Zhao, Shenzhen Ren and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gen LiState Key Laboratory of Reliability and Intelligence of Electrical Equipment, Innovation and Research Institute of Hebei University of Technology in Shijiazhuang, School of Electrical Engineering, Hebei University of Technology, Tianjin, 300401, PR China.
Chunxiu CaiKey Laboratory of Molecular Biophysics of Hebei Province, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin, 300401, PR China.
Ning ZhangKey Laboratory of Molecular Biophysics of Hebei Province, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin, 300401, PR China.
Zijia WangKey Laboratory of Molecular Biophysics of Hebei Province, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin, 300401, PR China.
Mingzhe ZhangKey Laboratory of Molecular Biophysics of Hebei Province, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin, 300401, PR China.
Quan LiuKey Laboratory of Molecular Biophysics of Hebei Province, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin, 300401, PR China.
Siyu ChenKey Laboratory of Molecular Biophysics of Hebei Province, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin, 300401, PR China.
Yanfei ShangInstitute of Chemical Engineering, Hebei University of Technology, Tianjin, 300130, PR China.
Chengqing ZhaoSinopep-Allsino Bio Pharmaceutical Co., Ltd., Lianyungang Economic and Technological Development Zone, Jiangsu, 222000, PR China.
Shenzhen RenKey Laboratory of Molecular Biophysics of Hebei Province, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin, 300401, PR China.
Hailong AnState Key Laboratory of Reliability and Intelligence of Electrical Equipment, Innovation and Research Institute of Hebei University of Technology in Shijiazhuang, School of Electrical Engineering, Hebei University of Technology, Tianjin, 300401, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The calcium-activated chloride channel TMEM16A is frequently overexpressed in breast cancer, establishing a reciprocal activation loop with EGFR signaling pathways that play a crucial role in the proliferation of breast cancer. Consequently, the simultaneous targeting of TMEM16A and EGFR may be a promising, yet underexplored, therapeutic strategy for breast cancer. Herein, we developed a carrier-free polyphenol nanonetwork (PFGH) using procyanidin (PC), a natural polyphenolic TMEM16A inhibitor, via coordination with Fe

Indexed as

Breast cancerCalcium-activated chloride channel TMEM16ACarrier-free polyphenol nanonetworkEpidermal growth factor receptorSynergistic therapy

Identifiers

PMID41158712
PMCPMC12554887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.